Andrew Zupnick, PhD

Andrew Zupnick, PhD, currently serves as Vice President of Oncology Drug Development at Catalyst Clinical Research, LLC since May 2020. Previously, Andrew Zupnick held positions as Vice President of Oncology Strategy at IQVIA and Novella Clinical, reflecting extensive experience in oncology strategy and business development. Andrew Zupnick's career began at Prologue Research, where roles progressed from Marketing Manager to Director of Business Development & Marketing before the company's acquisition by Novella Clinical. Educational qualifications include a Bachelor of Science in Biology from the Massachusetts Institute of Technology and a Doctorate in Cell and Molecular Biology from Columbia University, with research focused on the p53 tumor suppressor.